Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1621 1797
This examiner grants 62% of resolved cases
Kyle Gregory Nottingham examines cases in Art Unit 1621 and Tech Center 1700. He has 115 resolved cases with an allowance rate of 61.7 percent. The median days to allowance is 1202, which indicates a significant duration for successful prosecution. Practitioners should expect a timeline that spans many days in Tech Center 1700.
The interview lift is 31.9 percent, which significantly enhances the 61.7 percent baseline. For the 115 cases resolved, the 1202-day median pendency is a key factor to consider. Practitioners should prioritize interviews to leverage the 31.9 percent lift and improve their chances in Art Unit 1621. The 61.7 percent allowance rate indicates a fair probability of success, especially when combined with proactive communication strategies during the 1202-day process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18707089 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | Non-Final OA | The Regents of the University of California |
| 18721824 | COMPOUNDS FOR TREATMENT OF CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18578361 | IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME | Non-Final OA | University of Cincinnati |
| 17970448 | Magnetic-Responsive Photosensitizer Nanoplatform and Uses Thereof | Final Rejection | University of Maryland, Baltimore |
| 18789814 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Non-Final OA | Boehringer Ingelheim International GmbH |
| 19045439 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF OBESITY AND OBESITY-INDUCED DISEASE | Non-Final OA | Apogee Biotechnology Corporation |
| 17850720 | COMPOSITIONS AND METHODS FOR OPTOCHEMICAL CONTROL OF MTOR SIGNALING AND MTOR-DEPENDENT AUTOPHAGY | Final Rejection | The University of Hong Kong |
| 17627988 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | Non-Final OA | CAAMTECH, INC. |
| 17924101 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | Non-Final OA | DURECT CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy